Home
About
Overview
Sharing Data
ORCID
Help
History (9)
Thymoma and thymic carcinomas.
Is There an Interplay between Immune Checkpoint Inhibitors, Thromboprophylactic Treatments and Thromboembolic Events? Mechanisms and Impact in Non-Small Cell Lung Cancer Patients.
Adverse events self-reported by patients with extensive-stage small-cell lung cancer in the phase III CASPIAN study.
SMO mutations confer poor prognosis in malignant pleural mesothelioma.
Strategic advancements in targeting the PI3K/AKT/mTOR pathway for Breast cancer therapy.
See All 9 Pages
Find People
Find Everything
Login
to edit your profile (add a photo, awards, links to other websites, etc.)
Edit My Profile
My Person List (
0
)
Return to Top
Strategic advancements in targeting the PI3K/AKT/mTOR pathway for Breast cancer therapy.
Strategic advancements in targeting the PI3K/AKT/mTOR pathway for Breast cancer therapy. Biochem Pharmacol. 2025 06; 236:116850.
View in:
PubMed
subject areas
Animals
Antineoplastic Agents
Breast Neoplasms
Female
Humans
Molecular Targeted Therapy
Phosphatidylinositol 3-Kinases
Protein Kinase Inhibitors
Proto-Oncogene Proteins c-akt
Signal Transduction
TOR Serine-Threonine Kinases
authors with profiles
Ravi Salgia